DV
Dividend Vision

CRSP — CRISPR Therapeutics AG

CRISPR Therapeutics AG (CRSP)

Total return is 280.1% over the past 9.8 years, 43.1 points behind SPY at 323.2%. Its deepest 1-year drawdown was 42.3%.

CRISPR Therapeutics AG is a single-stock equity holding focused on gene-editing biotechnology rather than a diversified ETF strategy. The company does not pay dividends or make distributions, making it unsuitable for income-focused investors seeking regular payouts. This holding appeals primarily to growth-oriented investors interested in exposure to CRISPR gene-editing technology and its potential therapeutic applications.

CRSP key facts

Asset type
Stock
Asset class
Equity
Inception date
10/19/2016
Distribution frequency
None
Last close
$53.55
Market cap
$5,177,891,840
Average volume
807600.0
Beta
1.738
Payout ratio
0.0
Forward P/E
23.3645
EPS
$-4.71